Firm / Organisation

Belmore Neidrauer LLP

Current View:
Also ranked in:

This content is provided by Belmore Neidrauer LLP.

Managing Partner: Peter Wilcox
Number of partners: 3
Number of lawyers: 9
Languages: English

Firm Overview:
Belmore Neidrauer LLP is a leading intellectual property litigation firm based in Toronto, Canada. The firm has experience in all aspects of intellectual property law including patents, trademarks, copyright and misuse of confidential information. The firm has particular expertise in complex pharmaceutical and biotechnology patent litigation, often having multi-jurisdictional aspects.

The firm has a record of success in cases before trial and appellate courts, and in the Supreme Court of Canada. The firm’s partners are leaders in intellectual property litigation who are known for their experience, strategic thinking, creativity, and advocacy skills.

Main Areas of Practice:

■ Representing Janssen in a patent infringement action against Teva regarding a proposed generic version of paliperidone palmitate
■ Representing Janssen in patent infringement actions against Apotex, Pharmascience and Dr. Reddy’s regarding proposed generic versions of abiraterone
■ Represented National Oilwell Varco in a patent infringement action
■ Representing Pfizer in a patent action commenced by Seedlings Life Science Ventures relating to Pfizer’s epinephrine injection product
■ Represented AbbVie in a patent case against Samsung Bioepis with respect to the proposed approval and sale of a biosimilar version of adalimumab
■ Represented Eli Lilly and Daiichi Sankyo in a patent case against Apotex with respect to the proposed approval and sale of a generic version of prasugrel hydrochloride
■ Represented Bayer in a patent infringement action against Apotex and Cobalt Pharmaceuticals involving the sale of oral contraceptives. The Court granted Judgment in favour of Bayer, imposed a permanent injunction, and gave Bayer the right to elect between damages and profits
■ Represented Janssen in an action against Teva to quantify the damages it suffered by the infringement of a patent pertaining to an antibiotic. The Court awarded Janssen more than $18MM in damages. The judgment was upheld on appeal
■ Represented Gilead Sciences on appeal from a decision in which a patent owned by Idenix Pharmaceuticals was held to be invalid for insufficiency and inutility. The judgment was upheld on appeal
■ Represented Pfizer in an action by Teva under the damages provisions of the Patented Medicines (Notice of Compliance) Regulations
■ Represented the Intellectual Property Institute of Canada as an intervener in a precedent-setting case before the Supreme Court of Canada relating to patent utility
■ Represented Janssen in a patent case against Actavis with respect to the proposed approval and sale of a generic version of methylphenidate. At trial, Janssen’s patent was held to be valid and approval of the generic product was enjoined until after patent expiry

Key Clients:
■ Janssen (J&J)
■ Pfizer
■ AbbVie
■ Bayer
■ Eli Lilly
■ Gilead Sciences

■ Peter Wilcox
Tel: 416 863 3363
Email: [email protected]
■ Jason Markwell
Tel: 416 863 3383
Email: [email protected]